The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia [1]

British Journal of Haematology

Volumn 130, Issue 6, 2005, Pages 964-965

  Sulong, Sarina ^a   Case, Marian ^a   Minto, Lynne ^a   Wilkins, Bridget ^b   Hall, Andy ^a   Irving, Julie ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Childhood acute lymphoblastic leukaemia; Jak2; Mutation

Indexed keywords

HORMONE RECEPTOR; JANUS KINASE 2; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CHROMOSOME TRANSLOCATION; GENE MUTATION; HUMAN; LETTER; LEUKEMIA CELL LINE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTOPENIA; ACUTE LYMPHOCYTIC LEUKEMIA; GENETICS; MUTATION; POLYMERASE CHAIN REACTION;

CHILD; HUMANS; JANUS KINASE 2; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 27244450310     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05697.x     Document Type: Letter

References (8)

1. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassiliou G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. ( 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
2. Carron C. Cormier F. Janin A. Lacronique V. Giovannini M. Daniel M.T. Bernard O. Ghysdael J. ( 2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood, 95, 3891 3899.
3. Cools J. Peeters P. Voet T. Aventin A. Mecucci C. Grandchamp B. Marynen P. ( 1999) Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia. Cytogenetics and Cell Genetics, 85, 260 266.
4. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. Tichelli A. Cazzola M. Skoda R.C. ( 2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
5. Lacronique V. Boureux A. Valle V.D. Poirel H. Quang C.T. Mauchauffe M. Berthou C. Lessard M. Berger R. Ghysdael J. Bernard O.A. ( 1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 278, 1309 1312.
6. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. ( 2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
7. Meydan N. Grunberger T. Dadi H. Shahar M. Arpaia E. Lapidot Z. Leeder J.S. Freedman M. Cohen A. Gazit A. Levitzki A. Roifman C.M. ( 1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 379, 645 648.
8. Peeters P. Raynaud S.D. Cools J. Wlodarska I. Grosgeorge J. Philip P. Monpoux F. Van Rompaey L. Baens M. Van den Berghe H. Marynen P. ( 1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood, 90, 2535 2540.